Here's a research subject request, that pays you for simply talking with them. Just as an FYI. Malecare is not receiving any compensation or grant money from the researchers or from the pharmaceutical company....we just think it's a reasonable request for information about men with advanced prostate cancer. Feel encouraged to email any questions or [...]
I have not had even two seconds to write about anything I saw at the AACR meeting. It will take me a few days to decompress and process my experience. In the mean time I thought I would share the following with you about inflammation and its role in survival and cancer: Researchers from the [...]
I am in Washington at the AACR conference so my blog posts might be irregular until next Thursday or Friday. I will try and share any interesting or important things I see or learn while at the conference. Joel T Nowak, MA, MSW
It was announced today that the phase I/II trial of MDV3100 demonstrated positive results. MDV3100 is a novel triple-acting oral androgen receptor antagonist, the common antagonist most of us are familiar with today is Casodex. These results were published in the online April 15 version of The Lancet. […]
As you already know, I am very interested and a strong believer in the future of immunologic therapy. I have written extensively about Provenge and last week I told you about a phase I clinical trial of a Vaccine Therapy for men with progressive stage D0 (non-metastatic) prostate cancer. (http://advancedprostatecancer.net/?p=1419). I want to now let [...]